Literature DB >> 21982055

In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial.

Nanja van Geel1, Reinhart Speeckaert, Ilse Mollet, Sofie De Schepper, Julie De Wolf, Esther P M Tjin, Rosalie M Luiten, Jo Lambert, Lieve Brochez.   

Abstract

In this study, we developed an in vivo vitiligo induction model to explore the underlying mechanisms leading to Koebner's phenomenon and to evaluate the efficacy of therapeutic strategies. The model consisted of 12 pigmented test regions on the back of generalized vitiligo patients that were exposed to three Koebner induction methods: cryotherapy, 755 nm laser therapy, and epidermal abrasion. In addition, four cream treatments (pimecrolimus, tacrolimus, steroid and placebo) were randomly applied. Koebnerization was efficiently induced by all three induction methods. In general, cryotherapy was the best method of Koebner induction, followed by 755 nm laser therapy and epidermal abrasion. Reproducible results were obtained, which showed enhanced depigmented surface areas and higher amounts of T lymphocytes in placebo-treated test zones compared to active treated areas. Tacrolimus and local steroids were better inhibitors of Koebner's process (P < 0.05) compared to pimecrolimus. Our in vivo vitiligo induction model is very informative to investigate vitiligo induction and to determine the efficacy of topical treatments in vitiligo. This proof of concept confirms the efficient comparison of head-to-head therapeutic strategies intra-individually in a standardized, specific and better timed way.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982055     DOI: 10.1111/j.1755-148X.2011.00922.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  10 in total

1.  Effect of combination of fractional CO2 laser and narrow-band ultraviolet B versus narrow-band ultraviolet B in the treatment of non-segmental vitiligo.

Authors:  Mohamed Bakr El-Zawahry; Naglaa Sameh Zaki; Marian Youssry Wissa; Marwah Adly Saleh
Journal:  Lasers Med Sci       Date:  2017-07-26       Impact factor: 3.161

2.  Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo.

Authors:  Roselyne Y Wagner; Flavie Luciani; Muriel Cario-André; Alain Rubod; Valérie Petit; Laila Benzekri; Khaled Ezzedine; Sébastien Lepreux; Eirikur Steingrimsson; A Taieb; Yvon Gauthier; Lionel Larue; Véronique Delmas
Journal:  J Invest Dermatol       Date:  2015-01-29       Impact factor: 8.551

3.  Vitiligo of the arm after COVID-19 vaccination.

Authors:  Rhea Singh; Jay L Cohen; Michael Astudillo; John E Harris; Esther E Freeman
Journal:  JAAD Case Rep       Date:  2022-06-20

Review 4.  Update on the pathogenesis of vitiligo.

Authors:  Helena Zenedin Marchioro; Caio César Silva de Castro; Vinicius Medeiros Fava; Paula Hitomi Sakiyama; Gerson Dellatorre; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2022-05-25       Impact factor: 2.113

5.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.

Authors:  K Ezzedine; H W Lim; T Suzuki; I Katayama; I Hamzavi; C C E Lan; B K Goh; T Anbar; C Silva de Castro; A Y Lee; D Parsad; N van Geel; I C Le Poole; N Oiso; L Benzekri; R Spritz; Y Gauthier; S K Hann; M Picardo; A Taieb
Journal:  Pigment Cell Melanoma Res       Date:  2012-05       Impact factor: 4.693

6.  Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma.

Authors:  Reinhart Speeckaert; Nanja Van Geel; Jo Lambert; Barbara Boone; Ines Chevolet; Mireille Van Gele; Marijn M Speeckaert; Lieve Brochez
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

Review 7.  Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases.

Authors:  Carmen Rodriguez-Cerdeira; Elena Sanchez-Blanco; Alberto Molares-Vila
Journal:  Mediators Inflamm       Date:  2012-11-01       Impact factor: 4.711

8.  Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy.

Authors:  Rebecca L Riding; Jillian M Richmond; Keitaro Fukuda; John E Harris
Journal:  Pigment Cell Melanoma Res       Date:  2020-10-26       Impact factor: 4.159

9.  Multivariate Analysis of Factors Associated with the Koebner Phenomenon in Vitiligo: An Observational Study of 381 Patients.

Authors:  Huma Khurrum; Khalid M AlGhamdi; Khalid M Bedaiwi; Naif Meshael AlBalahi
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

10.  Cistanche deserticola polysaccharide induces melanogenesis in melanocytes and reduces oxidative stress via activating NRF2/HO-1 pathway.

Authors:  Yibo Hu; Jinhua Huang; Yixiao Li; Ling Jiang; Yujie Ouyang; Yumeng Li; Lun Yang; Xiaojiao Zhao; Lihua Huang; Hong Xiang; Jing Chen; Qinghai Zeng
Journal:  J Cell Mol Med       Date:  2020-02-25       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.